Investigating the role of RNA modifications in Duchenne muscular dystrophy
Official title: N6-Methyladenosine Methylome in Duchenne Muscular Dystrophy
Funded at State University of New York at Albany · NIH-10802344 · Data updated 2026-11-12
This study is looking at how a special change in RNA, called m6A, affects muscle growth and healing in boys with Duchenne muscular dystrophy (DMD), with the hope of finding new ways to help treat this challenging condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | March 6, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $200,383 |
| NIH project number | 5R21AR080936-02 |
| Project ID | NIH-10802344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are boys aged 0-11 years diagnosed with Duchenne muscular dystrophy.
✕Less likely to help
Patients with other forms of muscular dystrophy or those outside the specified age range may not benefit from this research.
What this research studies
This research focuses on understanding how a specific chemical modification of RNA, known as N6-methyladenosine (m6A), affects the progression of Duchenne muscular dystrophy (DMD), a severe muscle degenerative disease primarily affecting boys. By studying the mechanisms of m6A regulation, the researchers aim to uncover how it influences muscle cell development and regeneration in DMD. The approach involves analyzing the levels of m6A marks and the proteins that add or remove these modifications during muscle cell differentiation and in the context of DMD. This could lead to new insights into potential therapeutic targets for this devastating condition.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that improve muscle function and quality of life for children with Duchenne muscular dystrophy.
How similar studies have gone: While the specific focus on m6A in DMD is relatively novel, similar approaches in epitranscriptomics have shown promise in other diseases, indicating potential for success.
Where this research is happening
-
State University of New York at Albany
Albany, United States Active
Researchers
- Principal investigator: Dey, Bijan K — State University of New York at Albany
- Study coordinator: Dey, Bijan K
Related research
Other NIH-funded projects on the same topics.
-
Advancing manufacturing and release testing for a Duchenne gene editing therapy
A project to optimize how a dual-vector AAV gene editing treatment for Duchenne muscular dystrophy is made and tested, so it can move toward clinical use.
-
Understanding why Duchenne Muscular Dystrophy worsens and how to stop it
A research team at USC is studying Duchenne muscular dystrophy to find out why the disease continues to progress and how to interrupt harmful changes in muscle tissue.
-
Stopping steroid-related muscle and bone wasting in Duchenne muscular dystrophy
Researchers are testing ways to protect muscles and bones in people with Duchenne muscular dystrophy who take long-term steroid medicines.
-
MR clues to how nNOS affects energy use and blood flow in Becker and Duchenne muscular dystrophy
This project looks at how advanced MRI tests can track muscle energy and blood flow changes in people with Becker and Duchenne muscular dystrophy as new gene therapies are explored.
-
Digital motor-skill tracking for infants with Duchenne Muscular Dystrophy using wearables
A wearable-sensor project aims to quietly track and quantify how motor skills develop in babies and young boys with Duchenne Muscular Dystrophy.
-
Genetic factors that influence Duchenne Muscular Dystrophy progression
A study to find genes that change how severe Duchenne muscular dystrophy is in boys and young men, using patient data and DNA samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.